Haibu Pharmaceutical achieved great success at the 2019 Nanchang API CHINA exhibition.
Classification:
Company News
Release time:
2019-10-15
From October 10 to 11, 2019, Haibu Pharmaceutical participated in the 23rd China International Pharmaceutical (Industrial) Exhibition and Technology Exchange Conference and the 83rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair held in Nanchang City, Jiangxi Province, presenting a highly integrated professional and participatory industry exchange event for industry professionals.
At this exhibition, Haibu Pharmaceutical attracted many peers and clients to discuss business due to its advanced technology and high-quality products and services. Sales personnel engaged in deep communication with clients regarding technical challenges and our advantageous products. Our R&D strength and technical capabilities received unanimous recognition from clients, leading to intentions for cooperation.
During the exhibition, Dr. Zhang Xu, the API R&D Director of the company, delivered a professional report titled 'API Selection in the R&D Registration Process of Chemical Drug Formulations' at the 'Second MAH Development New Opportunities and Challenges - API China Forum and Industry Chain Innovation Model Discussion Meeting'. In his report, Dr. Zhang reviewed national policies over the years and explained key factors of concern from both formulation clients' and API suppliers' perspectives while listing various ways for mutual cooperation between them. This provided new ideas for many industry professionals regarding API selection in the R&D registration process of chemical drug formulations.
Haibu Pharmaceutical consistently adheres to the core values of 'Integrity, Professionalism, Cooperation, Win-Win', striving to perfect technology and products with rigorous and efficient R&D capabilities as well as innovative technologies to repay customers and society!
[Introduction to Haibu Pharmaceutical]
Beijing Haibu Pharmaceutical Technology Co., Ltd. was established in April 2005 (stock code: 836438) as a high-tech enterprise engaged in the full industrial chain of research, production, and sales of chemical drugs. The company's main business covers pharmaceutical science and clinical CRO services, R&D of high-end raw materials and pharmaceutical intermediates along with related registration and custom production. It also conducts research on chemical drug formulations and MAH business. The R&D products involve multiple fields such as anti-tumor, anti-depression, cardiovascular diseases, digestive system issues, respiratory system problems.
In China, it has obtained more than 60 drug clinical trial approvals along with over 10 new drug certificates and drug registration approvals. More than ten series of high-end raw materials and intermediate products have achieved commercial production with global market promotion and sales.
The company is committed to optimizing innovative synthesis processes for chemical drugs. It has achieved a series of excellent results in innovative technology applications such as efficient asymmetric catalysis, enzyme catalysis, continuous flow reaction technology; challenging crystal forms; process technology patents; small molecule structural modifications; having applied for more than ten related invention patents with ten granted.
[Cooperation Information]
Business Cooperation:
Contact Person: Chen Zhutuo Phone: 18010182349 Email: chenzhutuo@hopelife.cn
API Cooperation:
Contact Person: Yu Fuqiang Phone: 15010704183 Email: yufuqiang@hopelife.cn
Pharmaceuticals, R&D, Technology, API, Products, Customers, Chemistry, Registration, Innovation
Beijing Hope Pharmaceutical Co., Ltd.
